Valeant Pharmaceuticals Completes Divestiture of Generic Dermatology Products to Mylan

08.02.2012 - Valeant Pharmaceuticals International, Inc. announced that it has completed the divestiture of 1% clindamycin and 5% benzoyl peroxide gel (IDP-111), a generic version of Benzaclin, and 5% fluorouracil cream, (5-FU), an authorized generic of Efudex, to Mylan Inc.. This action was required under the consent order issued by the Federal Trade Commission (FTC) as part of the acquisition of Dermik, a dermatology unit of Sanofi, which was completed in December 2011.